

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,946,778	08/07/1990	Ladner <i>et al.</i>			
	2	5,789,554	08/04/1998	Leung <i>et al.</i>			
	3	7,456,260	11/25/2008	Rybak <i>et al.</i>			
	4	2008/0248037	10/09/2008	Li <i>et al.</i>			
	5	2009/0214535	08/27/2009	Igawa <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	6	WO 99/12973	03/18/1999	WIPO			English abstract	
	7	WO 2004/003019	01/08/2004	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	8	ARNDT <i>et al.</i> , "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998)
	9	DUFNER <i>et al.</i> , "Harnessing phage and ribosome display for antibody optimization," <i>Trends Biotechnol.</i> , 24(11):523-529 (2006)
	10	CHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001)
	11	MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)
	12	PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993)
	13	WAKELEE <i>et al.</i> , "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors," <i>Ann. Oncol.</i> On-line publication (7/24/2009)
	14	WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)
	15	WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)
	16	YAGITA <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> , 95:777-783 (2004)
	17	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. Ser. No. 10/550,934, filed September 10, 2009, 75 pages
	18	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005	Group Art Unit 1647	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	19	KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages
	20	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 36 pages
	21	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages
	22	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	